Zobrazeno 1 - 10
of 10
pro vyhledávání: '"骨髓增殖性肿瘤"'
Publikováno v:
Zhongshan Daxue xuebao. Yixue kexue ban, Vol 40 (2019)
【目的】探讨程序性死亡受体-1（PD-1）、程序性死亡配体-1（PD-L1）及CD4+CD25+Foxp3+调节性T细胞（Treg）、CD4+/CD8+比值在JAK2V617F突变阳性骨髓增殖性肿瘤（MPN）患者骨髓中的表达及临床意义。【
Externí odkaz:
https://doaj.org/article/181fe8a3d0cb4bb6ac4c5403818f49a1
Publikováno v:
Chinese Journal of Hematology
目的 探讨真性红细胞增多症（PV）患者干扰素和（或）羟基脲治疗后症状负荷改善与血液学疗效之间的关系。 方法 对190例符合WHO（2016）诊断分型标准、接受干扰素和（或）羟基脲连续治疗
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f79420eba875bcbc5fdb95829457920
https://pubmed.ncbi.nlm.nih.gov/34547868
https://pubmed.ncbi.nlm.nih.gov/34547868
Publikováno v:
Chinese Journal of Hematology
目的 探讨骨髓增殖性肿瘤（MPN）巨核细胞病理特征及其与起始基因突变的相关性。 方法 收集2012年2月至2017年10月于中国医学科学院血液病医院就诊的160例初诊MPN患者，根据世界卫生组织（WH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0fa3e6b7627cd5d0c526eaf8d623125c
http://europepmc.org/articles/PMC7656079
http://europepmc.org/articles/PMC7656079
Publikováno v:
Chinese Journal of Hematology
目的 调查我国医师和患者对Ph阴性骨髓增殖性肿瘤（MPN）症状负荷、治疗目标和疾病管理的理解，探寻医师和患者对疾病治疗沟通的差异，观察MPN疾病负荷对患者生活的影响。 方法 采用国
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ea582fe58dfba298a05221f4e410ab0e
https://pubmed.ncbi.nlm.nih.gov/32810964
https://pubmed.ncbi.nlm.nih.gov/32810964
Publikováno v:
Chinese Journal of Hematology
目的 分析经典型BCR-ABL阴性骨髓增殖性肿瘤（MPN）的基因突变及临床特征。 方法 应用二代测序方法检测108例初诊BCR-ABL阴性MPN患者[原发性血小板增多症（ET）55例，真性红细胞增多症（PV）24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a3b55ecb82cc8b41b4cb7f3e540712fd
https://pubmed.ncbi.nlm.nih.gov/32810965
https://pubmed.ncbi.nlm.nih.gov/32810965
Publikováno v:
Zhongshan Daxue xuebao. Yixue kexue ban, Vol 32 (2011)
【目的】 研究干扰素-α在治疗骨髓增殖性肿瘤(MPN)中的疗效及对JAK2V617F基因表达的影响【方法】 分析73例应用干扰素-α治疗超过6个月的MPN患者的临床资料及JAK2V617F基因表达,并与同期单用羟
Externí odkaz:
https://doaj.org/article/7e0ab84760ad4754b80a8c95b86f5db7
Publikováno v:
Chinese Journal of Hematology
目的 探讨JAK2抑制剂Ruxolitinib对JAK2V617F突变阳性的骨髓增殖性肿瘤（MPN）细胞内基质金属蛋白酶（MMP）调控的影响。 方法 ①收集2012年1月到2015年12月保定市第一医院收治的40例未经治疗的JAK2V6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2895635eaddfd7bd931cf1bf4666b8eb
http://europepmc.org/articles/PMC7354179
http://europepmc.org/articles/PMC7354179
Autor:
Junqing, Xu, Zefeng, Xu, Jingya, Wang, Bing, Li, Xiujuan, Sun, Tiejun, Qin, Yue, Zhang, Hongli, Zhang, Liwei, Fang, Lijuan, Pan, Naibo, Hu, Shiqiang, Qu, Zhijian, Xiao
Publikováno v:
Chinese Journal of Hematology
To investigate the value of myeloproliferative neoplasms Symptom Assessment Form total symptom score (MPN-SAF-TSS)in assessing constitutional symptoms among Ph/BCR- ABL negative myeloproliferative neoplasm (MPN)patients.A cohort of 628 MPN patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8dc848e708401c998fd84b875284090a
https://pubmed.ncbi.nlm.nih.gov/26876249
https://pubmed.ncbi.nlm.nih.gov/26876249
Publikováno v:
Chinese Journal of Hematology
To detect JAK2 V617F mutation burden and its clinical implications in patients with myeloproliferative neoplasm (MPN).JAK2 V617F mutation burden were detected by using MGB Taqman probes and its clinical significance were retrospectively studied in 41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7ab7fa01174eb489c989dbad66b15165
http://europepmc.org/articles/PMC7342523
http://europepmc.org/articles/PMC7342523
Autor:
Ruiyuan, Tian, Xiuhua, Chen, Jianmei, Chang, Na, Zhang, Yanhong, Tan, Zhifang, Xu, Fanggang, Ren, Junxia, Zhao, Jie, Pan, Haixiu, Guo, Xiaojuan, Wang, Hongwei, Wang
Publikováno v:
Chinese Journal of Hematology
To identify the MPL L391-V392ins12 spliceosome and analyze its frequencies in patients with myeloproliferative neoplasms (MPN).MPL aberrant spliceosome was identified through reverse transcription polymerase chain reaction (RT-PCR)combined with cloni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::68593ce61c56416ceac742045cb24530
https://pubmed.ncbi.nlm.nih.gov/26304077
https://pubmed.ncbi.nlm.nih.gov/26304077